Trials / Completed
CompletedNCT00073151
A Study of ABT-751 in Patients With Non-Small Cell Lung Cancer
A Phase II Study of ABT-751 in Patients With Non-Small Cell Lung Cancer Refractory to Taxane Regimens
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with non-small cell lung cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-751 |
Timeline
- Start date
- 2003-09-01
- Completion
- 2006-01-01
- First posted
- 2003-11-18
- Last updated
- 2007-11-29
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00073151. Inclusion in this directory is not an endorsement.